Gene · 2817
Papers2,608
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,608
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Detection of small extracellular vesicles as biomarkers in tear enabled by shear-horizontal surface acoustic wave biosensor. | Talanta | 2027 | 42361474 | PubTator, text mining | PubMed |
| Immunomagnetic-MXene Bifunctional Probes for Ultrasensitive and Specific Terahertz Metasensing of Tumor-Derived Exosomes. | Adv Sci (Weinh) | 2026 | 42814503 | PubTator, text mining | PubMed |
| Association of Bilateral Vestibulopathy With the ZNF91/LINC01224 Locus: A Genome-Wide Association Study. | Neurol Genet | 2026 | 42751493 | PubTator, text mining | PubMed |
| Glypican-1 in Rhabdomyosarcoma: A Multi-omics Exploration of a Targetable Biomarker. | Recent Pat Anticancer Drug Discov | 2026 | 42708284 | PubTator, text mining | PubMed |
| Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer. | Biomark Res | 2026 | 42681683 | PubTator, text mining | PubMed |
| Graph-Based Multi-Omics Integration Reveals Prognostic Histone Modification Reader Genes and Candidate Drug Targets in Colorectal Cancer. | Genes (Basel) | 2026 | 42650041 | PubTator, text mining | PubMed |
| Ginsenoside RD2 inhibits gastric cancer progression by suppressing TRIM46-mediated DUSP1 ubiquitination and modulating the ERK signaling pathway. | J Pharmacol Sci | 2026 | 42481127 | PubTator, text mining | PubMed |
| TDGF1 Mediates the Oncogenic Effects of the OLMALINC/miR-3614-5p ceRNA Axis in Colon Cancer Through Nodal/Smad2 and Glypican-1/MAPK-AKT Signaling. | Cells | 2026 | 42439618 | PubTator, text mining | PubMed |
| Highly Efficient Isolation and Rapid Detection of Pancreatic Cancer-Derived Small Extracellular Vesicles by Specific Aggregation from Aptamer-Functionalized DNA Long Chains. | Anal Chem | 2026 | 42438137 | PubTator, text mining | PubMed |
| Glycocalyx disruption mediates HP-PRRSV-induced microvascular endothelial dysfunction and underlies astragalus polysaccharide's antiviral efficacy. | Open Vet J | 2026 | 42375276 | PubTator, text mining | PubMed |
| Glypican-1 targeted nanoplatform for pancreatic ductal adenocarcinoma: interpreting findings. | J Cancer Res Clin Oncol | 2026 | 42287441 | PubTator, text mining | PubMed |
| Glycosylation-independent functions for distinct glypican core proteins drive cell-specific responses in corticogenesis. | Proc Natl Acad Sci U S A | 2026 | 42275470 | PubTator, text mining | PubMed |
| Going with the flow: endothelial dysfunction in type 2 diabetes. | Function (Oxf) | 2026 | 42247140 | PubTator, text mining | PubMed |
| Investigation of a GPC1-targeted and LIFU-responsive nanoplatform with ADV effect for visualized chemo-sonodynamic therapy against pancreatic ductal adenocarcinoma. | J Cancer Res Clin Oncol | 2026 | 42228190 | PubTator, text mining | PubMed |
| Glypican-1: a modulator of neurodegenerative and tumorigenic pathways. | Front Neurosci | 2026 | 42222366 | PubTator, text mining | PubMed |
| Selective Recognition of Tumor-Derived EVs by EpCAM-Imprinted Polymers for Proteomic Biomarker Discovery. | Anal Chem | 2026 | 42117374 | PubTator, text mining | PubMed |
| A cell-impermeable kinase inhibitor uncovers outside-in signaling pathways that promote HIV-1 infection. | J Virol | 2026 | 42112903 | PubTator, text mining | PubMed |
| Glypican-1-targeted antibody-drug conjugate shows therapeutic efficacy in lung squamous cell carcinoma. | Lung Cancer | 2026 | 42096801 | PubTator, text mining | PubMed |
| Liquid Biopsy Differentiation of Pancreatic Cancer From Non-Cancerous Pancreatic Disease Using Dielectrophoresis-Recovered Nanoparticles Carrying Cell-Free DNA and Protein Biomarkers. | Small | 2026 | 41947711 | PubTator, text mining | PubMed |
| An Integrated Electrochemical Biosensor Array Enabling Extracellular Vesicles Disruption and Multiplexed Lung Cancer Biomarker Detection. | IEEE Trans Nanobioscience | 2026 | 41926394 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2817/papers